CD4 and melanoma: Granulocytic or monocytic MDSC derived from mice containing B16-F10 melanoma tumors appear to suppress proliferation in the setting of peptide presentation from DC to CD4+ T cells by 30.3 ± 2.9% and 20.3 ± 2.2%, respectively (Fig. 3B).